SPR Therapeutics Nabs FDA Clearance

July 28, 2016

SPR Therapeutics has received clearance from the FDA to market the Sprint Peripheral Nerve Stimulation (PNS) system.

This pain management device allows lead placement as far as two to three centimeters from the intended nerve.

The PNS is fully reversible, as the device is designed to be removed without surgery at the end of the 30-day treatment period. — Cynthia Jessup

View today's stories